Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

John Mascarenhas, Maria R. Baer, Craig Kessler, Elizabeth Hexner, Douglas Tremblay, Leah Price, Lonette Sandy, Rona Weinberg, Heike Pahl, Lewis R. Silverman, Judith D. Goldberg, Heidi Kosiorek, Amylou Dueck, Ronald Hoffman

Research output: Contribution to journalArticle

Original languageEnglish (US)
JournalLeukemia and Lymphoma
DOIs
StateAccepted/In press - Jan 1 2019

Fingerprint

Primary Myelofibrosis
lestaurtinib

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Mascarenhas, J., Baer, M. R., Kessler, C., Hexner, E., Tremblay, D., Price, L., ... Hoffman, R. (Accepted/In press). Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2018.1532509

Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. / Mascarenhas, John; Baer, Maria R.; Kessler, Craig; Hexner, Elizabeth; Tremblay, Douglas; Price, Leah; Sandy, Lonette; Weinberg, Rona; Pahl, Heike; Silverman, Lewis R.; Goldberg, Judith D.; Kosiorek, Heidi; Dueck, Amylou; Hoffman, Ronald.

In: Leukemia and Lymphoma, 01.01.2019.

Research output: Contribution to journalArticle

Mascarenhas, J, Baer, MR, Kessler, C, Hexner, E, Tremblay, D, Price, L, Sandy, L, Weinberg, R, Pahl, H, Silverman, LR, Goldberg, JD, Kosiorek, H, Dueck, A & Hoffman, R 2019, 'Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis', Leukemia and Lymphoma. https://doi.org/10.1080/10428194.2018.1532509
Mascarenhas, John ; Baer, Maria R. ; Kessler, Craig ; Hexner, Elizabeth ; Tremblay, Douglas ; Price, Leah ; Sandy, Lonette ; Weinberg, Rona ; Pahl, Heike ; Silverman, Lewis R. ; Goldberg, Judith D. ; Kosiorek, Heidi ; Dueck, Amylou ; Hoffman, Ronald. / Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis. In: Leukemia and Lymphoma. 2019.
@article{f00cc60001d643728b993e2118a7821d,
title = "Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis",
author = "John Mascarenhas and Baer, {Maria R.} and Craig Kessler and Elizabeth Hexner and Douglas Tremblay and Leah Price and Lonette Sandy and Rona Weinberg and Heike Pahl and Silverman, {Lewis R.} and Goldberg, {Judith D.} and Heidi Kosiorek and Amylou Dueck and Ronald Hoffman",
year = "2019",
month = "1",
day = "1",
doi = "10.1080/10428194.2018.1532509",
language = "English (US)",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",

}

TY - JOUR

T1 - Phase II trial of Lestaurtinib, a JAK2 inhibitor, in patients with myelofibrosis

AU - Mascarenhas, John

AU - Baer, Maria R.

AU - Kessler, Craig

AU - Hexner, Elizabeth

AU - Tremblay, Douglas

AU - Price, Leah

AU - Sandy, Lonette

AU - Weinberg, Rona

AU - Pahl, Heike

AU - Silverman, Lewis R.

AU - Goldberg, Judith D.

AU - Kosiorek, Heidi

AU - Dueck, Amylou

AU - Hoffman, Ronald

PY - 2019/1/1

Y1 - 2019/1/1

UR - http://www.scopus.com/inward/record.url?scp=85060643863&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85060643863&partnerID=8YFLogxK

U2 - 10.1080/10428194.2018.1532509

DO - 10.1080/10428194.2018.1532509

M3 - Article

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

ER -